Emedgene Secures $6M Series A Funding to Advance AI-Powered Genomic Interpretation Platform
VCBeat (WeChat Official Account: vcbeat) learned from foreign media that gene company Emedgene completed a $6 million Series A financing round on the morning of February 19, U.S. local time. This round was solely led by Olive Tree Ventures to fund Emedgene’s continued research and development of AI-based genomics.
With the advancement of technology, gene sequencing has become increasingly accessible, with costs dropping below $1,000. However, manual interpretation of results remains a lengthy and cumbersome research process that requires geneticists to analyze and explain each test, making it a labor-intensive task. Over time, the interpretation of genetic information has become the primary bottleneck in the development of gene sequencing.
Emedgene is the world’s first genetics company to offer fully automated interpretation of genetic information, enabling geneticists to interpret test results more quickly and accurately, reducing the time spent on interpretation and reporting, and improving work efficiency. By leveraging advanced AI technology, Emedgene significantly simplifies the process of interpretation and evidence presentation, achieving large-scale automated analysis of genetic data. Founded in 2015 and headquartered in Israel, Emedgene has been recognized by the Israeli Prime Minister and the Israel Innovation Authority as the most innovative healthcare startup.
Step 1: Establish a Knowledge Base
Emedgene first aggregates public genomics databases, published literature, and proprietary databases created by the Emedgene scientific team into a unified knowledge base. When harvesting public resources, the system identifies valuable and accurate data and automatically performs conflict resolution.
This is a dynamic master knowledge base that continuously updates with the latest data, encompassing comprehensive genomics-related knowledge for rapid retrieval by interpreters. Currently, this master knowledge base covers 28 million relevant publications.
Step 2: Build an NLP Engine to Enrich the Database
Emedgene has developed a natural language processing (NLP) engine that automatically reads newly published scientific literature, incorporates it into Emedgene’s comprehensive knowledge base, and prioritizes the data based on credibility according to criteria established by Emedgene scientists. This technology helps researchers save significant time in interpreting genetic information, enabling them to rapidly screen written literature for relevant cases.
Step 3: Develop an AI Assistant for Automated Analysis
Emedgene’s geneticists and algorithm developers jointly created a genomics AI assistant that automates numerous routine tasks, allowing geneticists to focus on interpreting genetic information. The AI assistant automatically captures the logic applied in analyzing genetic cases and integrates it into Emedgene Genomics AI. When new genetic data are input, the AI assistant identifies similar cases and applies the same logical framework for interpretation.
Step 4: Identify pathogenic variants and enhance AI logic
Once the AI assistant identifies a new pathogenic variant, Emedgene’s Genomics Research Department develops logical algorithms for that variant. These new algorithms are then integrated into Emedgene Genomics AI to be displayed in future similar cases, enabling continuous improvement of AI results.
Compared to traditional manual interpretation, Emedgene’s AI-driven genetic analysis increases genetic mutation identification by 160%, reduces report interpretation time by 80%, and discovers new disease-causing genes at twice the speed. Currently, the Emedgene platform has achieved a diagnostic rate of 60%.
Currently, only 30% of genetic cases can be fully interpreted on average, and the etiologies of approximately 4,000 genetic diseases remain unknown. Emedgene’s reliance on AI models for genetic interpretation may increase the success rate of case analysis and provide explanations for more genetic diseases with unidentified causes, representing a future trend in genomic interpretation.
About Olive Tree Ventures
Olive Tree Ventures is an early-stage venture capital firm primarily focused on healthcare and life sciences. Established in 2015 and headquartered in Israel, the firm manages $4 billion in assets and has invested in six biotechnology companies. Additionally, it has founded 12 independent companies, four of which have been acquired, while the remaining eight continue to operate.
(Editor: Wang Chan)